Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nesajar
- Development stage
- Unknown
- Lead developer
- Gelpharma
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
**Nesajar** is a marketed oral fixed-dose combination from Gelpharma containing pinaverium bromide 100 mg and dimethicone 300 mg in soft gelatin capsules. Pinaverium bromide acts as a gastrointestinal antispasmodic by inhibiting voltage-dependent calcium influx into intestinal smooth muscle, while dimethicone is a silicone-based antiflatulent that disrupts and coalesces gastrointestinal gas bubbles. It is marketed in Mexico for symptomatic relief associated with colitis and irritable bowel syndrome, including abdominal pain, intestinal cramps, bloating, and flatulence. ([gelpharma.com](https://gelpharma.com/productos/nesajar/))
- Brand names
- Nesajar
- Other names
- bromuro de pinaverio + dimeticonapinaverium bromide + dimethicone
02
Targets
CACNA1S (Voltage-dependent L-type calcium channel subunit alpha-1S)
Beyond the preview
Go deeper on Nesajar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nesajar.